Analytical Data
-
Gene name
BLZF1
- Application
-
Alternative Names
BLZF1; Blzf1l; GO45_HUMAN; GOLGIN 45; Golgin-45; JEM 1; JEM 1s; JEM-1; JEM1; MGC22497
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H2G9
-
Expression Region
1-400aa
-
AA Sequence
MTTKNLETKV TVTSSPIRGA GDGMETEEPP KSVEVTSGVQ SRKHHSLQSP WKKAVPSESP GVLQLGKMLT EKAMEVKAVR ILVPKAAITH DIPNKNTKVK SLGHHKGEFL GQSEGVIEPN KELSEVKNVL EKLKNSERRL LQDKEGLSNQ LRVQTEVNRE LKKLLVASVG DDLQYHFERL AREKNQLILE NEALGRNTAQ LSEQLERMSI QCDVWRSKFL ASRVMADELT NSRAALQRQN RDAHGAIQDL LSEREQFRQE MIATQKLLEE LLVSLQWGRE QTYSPSVQPH STAELALTNH KLAKAVNSHL LGNVGINNQK KIPSTVEFCS TPAEKMAETV LRILDPVTCK ESSPDNPFFE SSPTTLLATK KNIGRFHPYT RYENITFNCC NHCRGELIAL
-
Molecular Weight
71.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BLZF1, also known as the B-lymphocyte transcription factor, has emerged as a significant player in the regulation of immune responses and B cell differentiation. Its role in modulating key signaling pathways has garnered attention due to its implications in various immune-related disorders and cancers. Research on BLZF1 protein has increased, focusing on its potential as a biomarker for diagnosing diseases and as a therapeutic target in immunotherapy. Studies have shown that BLZF1 is involved in the transcriptional regulation of genes associated with B cell development and function, highlighting its importance in adaptive immunity. Furthermore, dysregulation of BLZF1 has been linked to autoimmune diseases and lymphomas, indicating that understanding this protein's mechanisms could lead to novel therapeutic approaches. As such, the characterization of BLZF1 and the development of recombinant protein for functional studies are crucial steps in elucidating its biological functions and therapeutic potential. Advances in recombinant DNA technology have facilitated the production of BLZF1, enabling researchers to investigate its structure-function relationships, interactions with other proteins, and effects on cellular pathways. Overall, ongoing research into BLZF1 is poised to enhance our understanding of immune regulation and contribute to new strategies in the treatment of immune-related disorders.
